- Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms
- Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution
Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to improve access to health benefits and reframe the conversation on psychedelics.
The company has sought to achieve its goals through its string of related businesses, which include Ketamine Wellness Centers, the largest chain of psychedelic wellness clinics in the country; Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the company’s eponymous psychedelic wellness event; as well as media and e-commerce platforms, Reality Sandwich, and Delic Radio.
Matt Stang, Co-founder and CEO of Delic Corp recently joined the Gamechangers LIVE podcast to share his perspective on the psychedelic industry and share insights into the evolution of Delic Corp into its current form (https://ibn.fm/ab0yt).
During the interview, Stang elaborated on his colorful background within the alternative drugs sector, a journey which began when he interned at High Times, a leading counterculture publication which would go on to become the voice for the cannabis industry.
“I started off as an intern. It’s one of those wonderful stories. I graduated from college and wrote a senior thesis on legalization of marijuana. My thesis was that, with the terrorist attacks of 9/11, we could bring conservatives on board to legalization with a ‘tax and regulate’ strategy,” Stang said. “I submitted it to a friend who was friends with the General Counsel. He read it, loved it, and asked me to come in and intern. So, a week after I graduated, I got an internship at High Times and worked my way up…”
Stang would ultimately go on to become the owner and operator of High Times, a position which he leveraged in his attempt to play a role in legalizing cannabis usage across several different states.
“Now, two-thirds or more of the country live under some form of cannabis legalization… The world is changing in front of our eyes. I think the same thing is happening with psychedelics, but on a greater level and federally legal, because you have the FDA reviewing favorable clinical data for multiple psychedelics right now,” he continued.
The movement to decriminalize psilocybin, the key active ingredient within psychedelic drugs, kicked off in earnest a few years ago, with Denver, Colorado becoming the first city to decriminalize psilocybin in May 2019. The cities of Oakland and Santa Cruz, California, followed suit and decriminalized psilocybin in June 2019 and January 2020, respectively (https://ibn.fm/lucZB). However, the movement has gained further momentum in recent times, with the likes of actor Will Smith commenting on his use of ayahuasca (https://ibn.fm/6vlWC), and musician Lil Nas X saying he couldn’t have written the number one album of the year without gaining inspiration from a full-day mushroom trip alongside his producers (https://ibn.fm/5N3Zs).
During the podcast, Stang also went on to elaborate on the beneficial nature of psychedelic drugs and its ability to effectively supplant traditional benzodiazepines.
“You’ve got tons of people stuck on Xanax or Percocet or all of these ‘maintenance’ drugs that don’t actually change you at all. You take them every day and, for the four to six hours that they’re active, you feel better. When they wear off, you feel worse,” Stang added. “With our internal data, the ketamine that we utilize is having somewhere between a 70-80% efficacy rate, meaning people are curative or better from using it for a certain period of time. With MDMA, they had a 77% rate. With psilocybin, it was closer to 80%.
The full podcast interview with Delic Corp Co-Founder and CEO, Matt Stang can be found here: https://youtu.be/QIF12RiuAOQ
For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
